

this typographical error. As can be seen in the above amended specification (and in the Sequence Listing submitted in this application), the sequence described on line 18 of page 38 was intended to be labeled SEQ ID NO:13. As the sequence of page 38, line 18, is fully described in the submitted Sequence Listing as SEQ ID NO:13, a new sequence listing (as well as a new statement under 37 CFR 1.821) is not necessary. In light of the attached amendment, it is requested that the objections to the Sequence Listing and/or Specification be withdrawn.

In the event any fees are required with this paper, please charge Deposit Account No. 01-2300, referring to client-matter number 100564-09035.

Respectfully submitted,
ARENT FOX KINTNER PLOTKIN & KAHN PLLC



D. Daniel Dzara, II
Attorney for Applicants
Registration No. 47,543

Customer No.: 004372
1050 Connecticut Avenue, NW, Suite 400
Washington, DC 20036-5339
Telephone: (202) 857-6000

DDD:

Enclosures: Marked Up Copy of Specification
Communication dated July 15, 2002

MARKED UP COPY OF SPECIFICATION

Page 38, line 18:

GMAALPRLIAFTSE [(SEQ ID NO:14)] (SEQ ID NO:13) 0.8